New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:55 EDTBTX, CUR, ASTM, STEM, GERN, OSIRSupreme Court turns down appeal over stem cell research, SCOTUSblog says
The Supreme Court turned down an appeal by scientists seeking to stop all studies on embryonic stem cells, according to SCOTUSblog. The Fly notes that companies engaged in the research, development, and commercialization of stem cell therapies include StemCells (STEM), Neuralstem (CUR), Aastrom Biosciences (ASTM) and Osiris Therapeutics (OSIR). Also, earlier this morning, BioTime (BTX) entered into an agreement to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's (GERN) human embryonic stem cell programs. Reference Link
News For STEM;CUR;OSIR;ASTM;BTX;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
08:06 EDTSTEMStemCells transplants first participant in Phase II clinical trial
Subscribe for More Information
December 16, 2014
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:20 EDTGERNGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
12:01 EDTBTXBioTime unit, GE Healthcare sign set of license agreements, terms not disclosed
BioTime (BTX) announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare (GE) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
11:01 EDTBTXBioTime completes initial enrollment of urine-based bladder cancer test trial
BioTime and its subsidiary OncoCyte Corporation announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated. The goal of this clinical study was to assess the performance of OncoCyte’s proprietary diagnostic technology in detecting the most common type of bladder cancer; namely, urothelial carcinoma. The ability of the markers tested in the studies to determine the absence, presence, or progression of UC in patients will determine the specific nature of the bladder cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue.
December 12, 2014
14:52 EDTBTXBioTime to host investor and analyst meeting
Subscribe for More Information
December 8, 2014
08:11 EDTGERNGeron to host analyst and investor meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use